Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tissue Regenix ( (GB:TRX) ) has issued an announcement.
Tissue Regenix announced an 8% increase in revenue to $28.4 million for 2024, marking its second full year of profitability. The growth was driven by the dCELL® segment and core DBM products, despite challenges in other areas. The company is divesting its non-strategic German joint venture, GBM-V, to enhance growth and profitability, and continues to explore strategic options while maintaining a strong cash position supported by a revolving line of credit.
More about Tissue Regenix
Tissue Regenix is a leading company in the regenerative medical devices industry, utilizing patented decellularisation technology to create acellular tissue scaffolds for medical applications in sports medicine, foot and ankle injuries, and wound care. The company expanded its capabilities with the acquisition of CellRight Technologies, which develops innovative tissue scaffolds for various surgical procedures.
YTD Price Performance: -1.67%
Average Trading Volume: 35,217
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £42.03M
Find detailed analytics on TRX stock on TipRanks’ Stock Analysis page.
